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A B S T R A C T
Ethnopharmacological relevance: The discovery of the antimalarial agent artemisinin is considered one of the
most signiﬁcant success stories of ethnopharmacological research in recent times. The isolation of artemisinin
was inspired by the use of Artemisia annua in traditional Chinese medicine (TCM) and was awarded a Nobel Prize
in 2015. Antimalarial activity has since been demonstrated for a range of other Artemisia species, suggesting that
the genus could provide alternative sources of antimalarial treatments. Given the stunning diversity of the genus
(c. 500 species), a prioritisation of taxa to be investigated for their likely antimalarial properties is required.
Materials and methods: Here we use a phylogenetic approach to explore the potential for identifying species more
likely to possess antimalarial properties. Ethnobotanical data from literature reports is recorded for 117 species.
Subsequent phylogenetically informed analysis was used to identify lineages in which there is an over-
representation of species used to treat malarial symptoms, and which could therefore be high priority for further
investigation of antimalarial activity.
Results: We show that these lineages indeed include several species with documented antimalarial activity. To
further inform our approach, we use LC-MS/MS analysis to explore artemisinin content in ﬁfteen species from
both highlighted and not highlighted lineages. We detected artemisinin in nine species, in eight of them for the
ﬁrst time, doubling the number of Artemisia taxa known to content this molecule.
Conclusions: Our ﬁndings indicate that artemisinin may be widespread across the genus, providing an accessible
local resource outside the distribution area of Artemisia annua.
1. Introduction
Malaria is one of the most prevalent life-threatening diseases of
humanity, with serious social and economic impacts (Sachs and
Malaney, 2002). According to the World Health Organization (WHO),
almost half of the world's population is at risk of contracting malaria
(World Health Organization, 2015). In 2015 alone, 214 million new
cases were reported, resulting in 438,000 fatalities, with Sub-Saharan
Africa bearing 89% of global cases and 91% of deaths (World Health
Organization, 2015). Currently, the main antimalarial treatment is
based on the potent sesquiterpene lactone artemisinin.
The discovery of artemisinin was inspired by the use of Artemisia
annua L. (Asteraceae), known as qinghaosu in traditional Chinese
medicine (TCM) (Klayman, 1985). It is certainly considered one of the
most signiﬁcant success stories of ethnopharmacological research in
recent times, and was awarded a Nobel Prize in Physiology or Medicine
in 2015 (Normile, 2015). Artemisinin gained importance as an alter-
native to quinine-based treatments for malaria in the 1970's, at a time
when the malaria parasite (e.g. Plasmodium falciparum Welch) was
starting to develop resistance to existing treatments (Tu, 2011, 2016,
2017). Nonetheless, parasite resistance to artemisinin has been detected
in Southeast Asia in recent years (World Health Organization, 2015),
raising concerns about the future eﬃciency of artemisinin as an anti-
malarial agent. Drug resistance is a persistent problem in the treatment
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and prevention of malaria, and continuous discovery and development
of alternative antimalarial agents are needed to ensure the availability
of reliable treatment options in the future.
Antimalarial activity has recently been demonstrated for several
other Artemisia species (Mojarrab et al., 2014, 2015), suggesting that
this genus of circa 500 species could provide much-needed alternative
sources of antimalarial treatments. Artemisia is widely distributed in the
northern hemisphere, reaching South America and North Africa, across
a diverse range of habitats, and presenting diﬀerent life forms
(Mucciarelli and Maﬀei, 2002). Given the stunning diversity in the
genus, a prioritisation of taxa to be investigated for their likely anti-
malarial properties is required. Several species of Artemisia are used as
food ﬂavourings (e.g. tarragon: A. dracunculus L.), drink additives (e.g.
absinth: A. absinthium L.; genipi: A. genipi Stechm.), and in traditional
medicine across the distribution range of the genus (Abad et al., 2012).
Approximately 300 Artemisia species have been investigated in variable
level of detail for their chemistry and bioactivity, and some have de-
monstrated antimalarial bioactivity (Tan et al., 1998; Wilcox, 2009;
Vallès et al., 2011, and references therein). Besides artemisinin, a re-
markable diversity of bioactive compounds has been recorded to exist
in species with demonstrated antimalarial bioactivity, such as in A.
abrotanum L. (Cubukcu et al., 1990). In this species artemisinin is not
present, but a range of several coumarins, sesquiterpenes and ﬂavo-
noids has been reported (Cubukcu et al., 1990; Tan et al., 1998). This
suggests that Artemisia species can both provide alternative sources of
artemisinin as well as novel artemisinin analogues and other anti-
malarial compounds, potentially with diﬀerent modes of action. Fur-
thermore, diﬀerent compound types may act synergistically to delay the
development of drug resistance in the malaria parasite, suggesting that
combination therapies or herbal extracts rather than single compounds
may also result in more eﬃcient approaches in the future (Rasoanaivo
et al., 2011).
Recent research avenues have proposed that phylogenies can pro-
vide a rationale for the prioritisation of plant species for investigation.
By mapping traditional medicinal uses (Ernst et al., 2016; Forest et al.,
2007; Grace et al., 2015; Saslis-Lagoudakis et al., 2011, 2012), as well
as chemical and bioactivity data (Larsen et al., 2010; Rønsted et al.,
2012; Zhu et al., 2011) on phylogenetic trees, several studies have re-
ported that both traditional uses and demonstrable medicinal proper-
ties are concentrated around certain lineages, and largely absent from
others.
This phylogenetic pattern can help us mine traditional knowledge to
identify lineages with desired medicinal properties. Further, lineages
rich in traditional uses are also largely coincident with the ones over-
represented in species with pharmacological activity (Saslis-Lagoudakis
et al., 2012). Therefore, by identifying “hot nodes” (Saslis-Lagoudakis
et al., 2011) that are overrepresented in species with traditional uses, it
might be possible to detect lineages that are most likely to demonstrate
desired bioactivity. Hence, the use of phylogenies and traditional
knowledge could increase hit rates in bioprospecting by narrowing
down the number of potentially relevant species to be investigated for
bioactivity. When combined with chemical data, it is possible to further
focus investigations on the most promising species for alternative
sources of artemisinin for local use, as well as species more likely to
possess new leads with other modes of action.
The main objective of this study was to investigate how traditional
medicinal knowledge combined with phylogenies could be used to
identify Artemisia species with potential antimalarial bioactivity for
further exploration. We collated a comprehensive database of tradi-
tional medicinal uses for Artemisia, which we used to highlight lineages
with an overrepresentation of medicinally-used species on a compre-
hensive phylogeny of the genus. To validate our approach and explore if
presence of artemisinin may explain the reported use, we then used
high-performance liquid chromatography coupled to a mass/mass de-
tection (LC-MS/MS) to analyse a subset of ﬁfteen randomly-selected
species for artemisinin content representing the phylogenetic diversity
as well as species from both inside and outside hot nodes.
2. Materials and methods
2.1. Medicinal uses
Information on the ethnobotanical uses of the genus Artemisia was
collected based on a comprehensive literature review of published
sources obtained from searching in online databases using the keyword
"Artemisia" including reviews of the uses of the genus, primary ethno-
botanical studies, and reports from local ﬂoras. A total of 124 published
sources provided 1215 use records (Supplementary materials, Table
S1), which were classiﬁed into 23 use categories (Table 1) following the
Economic Botany Data Collection Standard (Cook, 1995) as also used in
other studies (Cámara-Leret et al., 2017; Ernst et al., 2016; Grace et al.,
2015). Additionally, we extracted records of uses for the prophylaxis or
treatment of symptoms related to malaria, namely antimalarial
(med_3), fever (med_9), infections (med_13) and insect repellents
(med_20) (Table 1, Table S1).
2.2. Phylogenetic reconstruction
Nuclear ribosomal DNA sequences (ITS1–5.8S-ITS2 and 5′ETS) were
downloaded from GenBank (Table S2) for a total of 244 Artemisia
species representing all subgenera described in the genus, primarily
from previous studies by Vallès et al. (2003), Tkach et al. (2008),
Pellicer et al. (2010a), (2010b), Hobbs and Baldwin (2013), Pellicer
et al. (2011), and Malik et al. (2017). Additionally, Lepidolopsis tur-
kestanica (Regel and Schmalh.) Poljakov and Tanacetum parthenium (L.)
Schultz Bip. were designated as outgroup species based on their phy-
logenetic proximity to Artemisia (Table S2; e.g. Malik et al., 2017).
Sequences were edited for each DNA marker using BioEdit v.7.0.9 (Hall,
1999) and aligned using CLUSTAL X (Thompson et al., 1997). Base gaps
and any inaccuracies found were manually adjusted. Preliminary
Bayesian inference (BI) was conducted to assess incongruence among
nuclear markers, and subsequent concatenated analysis was conducted
Table 1
Ethnobotanical use categories, analysis codes, and number of Artemisia species
reported in the literature for each category. The plant taxa are considered as
quoted in the original publications.
Use category Analysis
code
Focused
malaria
analysis
Number of
species
MEDICINAL (when no speciﬁc
category)
Med_0 19
ANTIHELMINTHIC Med_1 23
ANTI-INFLAMMATORY Med_2 21
ANTIMALARIAL Med_3 Y 23
ANTITOXIC Med_4 10
CANCER Med_5 9
CIRCULATORY SYSTEM Med_6 19
DERMATOLOGICAL Med_7 15
DIGESTIVE SYSTEM Med_8 34
FEVER Med_9 Y 23
GENITOURINARY SYSTEM Med_10 26
HALLUCINOGEN Med_11 2
IMMUNITARY DISORDERS Med_12 5
INFECTIONS Med_13 Y 52
METABOLIC DISORDERS Med_14 19
MUSCULOSKELETAL SYSTEM Med_15 13
NERVOUS SYSTEM Med_16 13
NUTRITIONAL DISORDERS Med_17 20
PAIN Med_18 12
PREGNANCY/BIRTH/
PUERPERIUM
Med_19 4
INSECT REPELLENTS Med_20 Y 2
RESPIRATORY SYSTEM Med_21 14
SENSORIAL DISORDERS Med_22 5
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after conﬁrming no conﬂicts on the phylogenetic signals. For this
analysis, a partitioned BI of the combined dataset was conducted with
MrBayes v.3.2.2 (Ronquist and Huelsenbeck, 2003) on the CIPRES
server (Miller et al., 2010). The most appropriate models for nucleotide
substitution were chosen with jModelTest v.0.1 (Posada, 2008), which
were GTR+G+I for ITS and GTR+G for ETS. Two independent runs of
four Markov Chain Monte Carlo (MCMC) analyses were run for 107
generations, sampling every 103 generations. The MCMC sampling was
evaluated with Tracer v.1.6 (Rambaut et al., 2014), conﬁrming that the
eﬀective sample size (ESS) was> 200 in each run. The ﬁrst 2500 trees
were discarded as the ‘burn-in’ period, and the remaining trees were
used to produce a 50% majority-rule consensus tree, with the posterior
probabilities (PP) of nodes calculated from the pooled samples.
2.3. Phylogenetic distribution of medicinal species
We explored the phylogenetic distribution of Artemisia species with
described medicinal uses with two main approaches as recommended
by Ernst et al. (2016) and described below. All analyses were performed
in the R environment v.3.0.3 (Core Team, 2015), based on scripts de-
veloped by Ernst et al. (2016).
With the ﬁrst approach, we aimed to estimate the overall degree of
phylogenetic clustering of the diﬀerent uses reported for Artemisia
species on the Artemisia phylogeny. We used the D metric (Fritz and
Purvis, 2010) implemented by the function “phylo.d” in the R package
caper (Orme, 2013) with the default parameter of 1000 permutations.
Thus, if a species trait - in our case species reported used in a use ca-
tegory - shows phylogenetic signal, it may be assumed that species in
this category are not randomly distributed over the phylogeny, but are
more phylogenetically clustered than expected by chance. Values of
D=1 indicate a phylogenetically random distribution, whereas D< 1
indicates phylogenetic clustering and D=0 indicates that the trait is
clustered as if it had evolved by Brownian motion of evolution (Fritz
and Purvis, 2010). Two p-values are furthermore calculated for the D
metric, p(D< 1) indicating whether the D metric is signiﬁcantly
smaller than 1, meaning that the trait (reported use) is not randomly
distributed over the phylogeny. The second p-value, p(D > 0) indicates
whether the D metric is signiﬁcantly greater than 0, meaning that the
trait has a signiﬁcantly diﬀerent distribution on the phylogeny from the
Brownian model of evolution. To account for phylogenetic uncertainty,
the D metric was calculated on 1000 randomly selected trees from
within the 95% credibility set of trees from our Bayesian analyses. This
was done for all medicinal species, as well as the diﬀerent categories of
use presented above for which there were more than ten species with
described uses.
With the second approach, we wanted to identify lineages on the
Artemisia phylogeny that are overrepresented in species used medicin-
ally. To do that, we searched for “hot nodes” (nodes that are sig-
niﬁcantly overrepresented by species in a given category) (Saslis-
Lagoudakis et al., 2011), using the “nodesigl” command in PHYLOCOM
v4.2 (Webb et al., 2008). This option uses the same community sam-
pling (the group of species used for a certain category of use) as de-
scribed above and tests each node of the phylogeny for overabundance
of terminal taxa distal to it. Observed patterns for each sample are
compared to those from random samples to provide signiﬁcance for the
observed overabundance. For a node that is identiﬁed through this
approach, the descendants of this node are signiﬁcantly more likely to
belong to the “community” under consideration than expected by
chance alone. Accordingly, this technique identiﬁes the exact position
of phylogenetic clumping on the phylogeny, namely the “hot” nodes for
a category of use (Saslis-Lagoudakis et al., 2011).
2.4. Artemisinin content determination
Plant material was obtained either directly in the ﬁeld or after
sowing achenes from wild populations and cultivating the plantlets in
the Institut Botànic de Barcelona until adult age. The plant material was
collected in all cases, irrespective of its provenance (germinated
achenes or vegetative material), either before ﬂowering or just when
ﬂowering period was starting. Vouchers are deposited in the herbaria
BCN (Centre de Documentació de Biodiversitat Vegetal, Universitat de
Barcelona), LE (Botanical Institute, Russian Academy of Sciences, Saint
Petersburg) or SSLP (Rocky Mountain Research Station, USDA Forest
Service, Provo, Utah). Plant samples, consisting of leaves from the
terminal third part of ﬁve plants per accession, were dried on absorbent
paper at room temperature in absence of light and humidity for ﬁfteen
days. Dried samples were pulverised in an electrical grinder; particle
size varied among species, with textures from granulate to spongy.
Following Misra et al. (2014) microwave-assisted extraction was car-
ried out for all samples, mixing 0.2 g of pulverised plant material in
20ml of hexane:acetone 1:1 in a recipient of a microwave extractor and
under the following conditions: Initial temperature ramp (from 100 °C
to 115 °C in 10min), extraction temperature and time: 115 °C during
15min. Initial and ﬁnal pressure: 50 psi and 155 psi, respectively. Fi-
nally, samples were left to cool down to room temperature before the
extracted samples were ﬁltered with polytetraﬂuorethylene (Teﬂon®)
meshes of 0.2 µm of pore diameter. The extracted samples were brought
to dryness and resuspended in acetonitrile, and were then analysed with
high-performance liquid chromatography coupled to a mass/mass de-
tection (LC-MS/MS) carried out on an API3000 (ABsciex) triple quad-
rupole mass spectrometer integrated on an Acquity (Waters) UPLC
system. Two replicates of 10 µl were analysed for each accession. A
Luna 2.5 µm C18 column (20 HST 50× 2.00mm, producer) was used
as stationary phase. The column temperature was set at 40 °C. The
mobile phase consisted of a mixture of (A) MilliQ Water with 0.1%
formic acid and (B) acetonitrile. The gradient elution proﬁle consisted
of: Initial conditions: A: 2%, B: 98%; 1min A: 2%, B: 98%; 3min A:
100%, B: 0%; 4min: A: 100%, B: 0%; 4.1 min A: 2%, B: 98%; 6min A:
2%, B: 98%. Flow was set at 0.7ml/min. Analytes were detected in
positive electrospray ionisation (ESI) mode. The ion spray voltage was
set at 4500 V and source temperature at 350 °C. Data was acquired in
MRM (multiple reaction monitoring) mode. Three replicates of the
extraction were used per accession, and two analyses were performed
per replicate. Transition selected was 283.3/209.1 for artemisinin. Ar-
temisinin content in weight/weight percentage of dried plant material
is reported in Table 2. Limit of detection is 1.2 ppb (ng/ml) and limit of
quantiﬁcation is 6 ppb (ng/ml) determined as 3 times and 10 times the
minimum value that could be detected respectively.
3. Results
3.1. Medicinal use of Artemisia species
We found reports of medicinal use for 117 scientiﬁc names (in-
cluding 8 subspecies and/or varieties) corresponding to 109 currently
accepted species (21% of the genus) of Artemisia in 23 medicinal use
categories. The primary categories included digestive system disorders
(34 species), infections (52 species), and genitourinary disorders (26
species) (Fig. 1, Table 1). Of these, 66 species (13% of the genus) were
speciﬁcally used as prophylaxis or treatment of symptoms related to
malaria, in the following categories: antimalarial (23 species), fever (23
species), infections (52 species) and insect repellents (2 species)
(Table 1, Table S1). Note that of the 117 species with reported ethno-
botanical uses, 77 were included in the phylogeny. Likewise, of the 66
species with malaria-related symptoms, 46 were included in the phy-
logeny.
3.2. Phylogenetic relationships in Artemisia
Our preliminary analyses (data not shown) did not reveal robust
incongruence on the overall tree topologies concerning supported
nodes, so the resulting 50% majority rule consensus phylogram
J. Pellicer et al. Journal of Ethnopharmacology 225 (2018) 1–9
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obtained from the concatenated ETS and ITS datasets is depicted in Fig.
S3. Note that the 5.8 S gene was excluded from the phylogenetic ana-
lysis since it was missing in several species (Table S2). The tree to-
pology we obtained largely corresponds to our current understanding of
the evolutionary relationships in Artemisia [see Malik et al. (2017) for
the most recent phylogenetic study of the genus]. The monophyly of the
genus is strongly supported (PP= 95%). Overall, the backbone of the
tree is largely resolved (PP > 90%), with the exception of some
lineages (see Fig. S3), as already found in previous attempts to untangle
the evolutionary relationships in the genus (e.g., Hobbs and Baldwin,
2013; Malik et al., 2017; Riggins and Seigler, 2012). Likewise, there are
several cases in which the traditional classiﬁcation of the species does
not fully correspond with the lineage segregation resulting from the
analysis of DNA sequence (Fig. S3).
3.3. Phylogenetic distribution of species with medicinal use
We mapped reported medicinal use of Artemisia species on the most
comprehensive phylogeny of the genus to date (Fig. 2) to investigate the
degree of phylogenetic clustering of species with medicinal uses using
two independent approaches, the D-metric, which explores overall
phylogenetic signal of a trait, and the hot nodes approach, which ex-
plores overabundance of a trait on individual nodes across the phylo-
geny (Table 3), focussing primarily on uses treating symptoms related
to malaria.
The D-statistic for clustering of medicinal uses on the tree was
smaller than 1 (D-median = 0.808; p(D<1): ns; Table 3), corre-
sponding to phylogenetic clustering, although this was not signiﬁcant.
Likewise, species used against malaria-related symptoms were clustered
based on D < 1, but again this was not signiﬁcant (D=0.746; p
(D < 1): ns; Table 3).
Using the "nodesig" command to identify hot nodes of species used
against malaria-related symptoms on the phylogeny (Fig. 2), we were
able to highlight four hot nodes including a total of 15 species that are
most likely to possess antimalarial properties based solely on the phy-
logenetic exploration of traditional medicinal uses (Table 4). These
lineages comprise species with documented antimalarial activity
(Table 4, Table S1), including Artemisia annua, A. absinthium, and A.
gorgonum, as well as A. arborescens, A. sieversiana and A. tridentata with
use reports for fever or infections, corroborating the validity of our
approach. Eight of the ﬁfteen species in the hot nodes are not associated
with any use reports in the literature, and therefore represent entirely
new lines of enquiry. It is likely that additional species could belong to
the identiﬁed hot nodes because the phylogenetic analysis included
only about half of the ca. 500 Artemisia species.
3.4. Artemisinin content
Artemisinin was detected in nine of the 15 investigated species
selected from both within and outside the hot nodes (Fig. 2, Table 2).
The two included accessions of Artemisia annua contained 140–286
times higher levels of artemisinin (0.069100% and 0.142000%) than A.
anethifolia, (0.000497%) which was the species with the second highest
content. This conﬁrms the value of A. annua as the hitherto best source
of artemisinin. Naturally, artemisinin is produced in small quantities,
which leads to a shortage of global supply. Artemisinin is diﬃcult to
chemically synthesize due to its complex structure, and A. annua re-
mains the main source of the drug, although current advances in ge-
netic and metabolic engineering may improve in planta production of
artemisinin in the future (Ikram and Simonsen, 2017). The detection of
artemisinin in four of seven species (A. absinthium, A. annua, A. mac-
rocephala, and A. thuscula) from hot nodes and ﬁve of eight (A. an-
ethifolia, A. frigida, A. gmelinii, A. integrifolia, and A. messerschmidtiana)
from outside the hot nodes suggests that the occurrence of artemisinin
is common throughout the genus. A further four species from the hot
nodes for which artemisinin content was tested but not conﬁrmed in the
present study (Table 2, Table S4), namely A. arborescens, A. herba-alba,
A. sieversiana and A. tridentata, have reported uses against fever and
infections.
4. Discussion
4.1. Phylogenetic prediction of antimalarial activity in Artemisia
We conducted a bibliographic review searching for Artemisia species
with reported traditional uses against malaria-related symptoms (66
species). In addition to the nine species found here to contain detectable
levels of artemisinin (Table 2), several other Artemisia species have
previously been reported to contain artemisinin (Table S4): A. abro-
tanum (Suresh et al., 2011) A. apiacea (Liersch et al., 1986), A. cina
(Aryanti et al., 2001), A. dubia (Kiani et al., 2012), A. hedinii (Ling,
2007), A. lancea (Tan et al., 1998), A. pallens (Suresh et al., 2011), A.
scoparia (Singh and Sarin, 2010), and A. sieberi (Arab et al., 2006) (18
species, Table 2, Table S4). Artemisinin has been detected for the ﬁrst
time in eight species (Table 2), almost doubling the number of species
in the genus known to contain this compound. It is notable that of the
several species found here to contain artemisinin, only A. annua was
previously known as a main source of the compound. Certainly, the
occurrence of artemisinin in so far 18 species across the phylogeny
(Table S4), suggests that the artemisinin biosynthetic pathway might be
an ancestral trait and the biosynthetic machinery needed to produce
artemisinin and related compounds is likely to be common for many
Artemisia species. The widespread distribution of the genus therefore
enables potentially a local use of alternative species for the treatment of
malaria.
Our phylogenetic predictions are only informed by traditional uses,
which are diﬃcult to classify (Staub et al., 2015), and not biochemistry
or bioactivity data. Using the D-statistic, we did not ﬁnd signiﬁcant
phylogenetic signal of neither medicinal use nor antimalarial activity,
but using the hot node approach, we were able to identify several
lineages within Artemisia with overrepresentation of species used for
antimalarial bioactivity and seven of the 15 species in the hot nodes
(including A. annua) have reported antimalarial use (Table 2).
Weak phylogenetic signal using the D-statistic was also reported by
Grace et al. (2015) for medicinal use in the genus Aloe and by Ernst
et al. (2016) for several use categories in the genus Euphorbia. Grace
et al. (2015) did not explore the hot nodes approach in their study, but
Ernst et al. (2016) was able to identify nodes that were signiﬁcantly
overrepresented by species showing inﬂammatory response although
the D-statistic of this category was not showing signiﬁcant clustering (p
(D<1) ns).
Whereas the hot nodes approach has been able to identify nodes
overrepresented by species with a speciﬁc trait both in the present
study and in the study by Ernst et al. (2016), the D-statistic approach
appears to be more conservative and potentially less useful for
Fig. 1. Number of Artemisia species cited in the literature for the prophylaxis or
treatment of malaria. In total 66 species are reported to be used for at least one
of the four categories. 46 of these are present in the phylogeny.
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Fig. 2. Hot nodes of Artemisia species used against malaria-related symptoms plotted on the 50% majority-rule consensus phylogram from Bayesian inference.
Published (red) and novel (green) records of artemisinin presence in Artemisia are also indicated.
Table 3
Phylogenetic signal (D-statistic) on 1000 phylogenetic trees of Artemisia per Economic Botany Data Collection Standard categories all medicinal (med_0-med_22) and
for prophylaxis or treatment of malaria related symptoms (antimalarial (med_3), fever (med_9), infections (med_13) and insect repellents (med_20). The prevalence
expresses the number of species within a category versus the total number of species (244).
Category N Prevalence D-statistic Phylogenetic signal
Median Range p(D<1)a Strengthb
All medicinal 77 0.32 0.81 0.65–0.94 ns Weak
Malaria related 46 0.19 0.75 0.46–0.95 ns Weak
N: number of species. a* p < 0.05 in 95% of trees, ** p < 0.05 in 95% of trees; ***p < 0.005 in all trees. bweak:< 90% p(D>0)> 0.05; moderate: p
(D> 0)> 0.05 in 90% of trees; strong: p(D>0)> 0.05 in 95% of trees; very strong: p(D>0)> 0.05 in all trees.
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identifying phylogenetic clustering. Future modelling studies may
provide a better understanding of whether the D-statistic approach is
underestimating phylogenetic signal under certain conditions and we
would also urge for the exploration of additional approaches to be used
for phylogenetic prediction in order to continue to develop this emer-
ging ﬁeld.
It should also be emphasized that phylogenetic prediction relies on
community sampling of a trait of interest and the approach is therefore
limited by availability of relevant trait data. Furthermore, while phy-
logenetic exploration oﬀers a new approach to exploration of medicinal
potential, many other approaches to enable drug discovery exists ran-
ging from ethnopharmacological surveys to combinatorial chemistry
approaches, each with diﬀerent advantages and limitations, which may
all be relevant tools depending on the objectives.
Despite the hypothesis that biosynthesis of artemisinin may be an
ancestral trait for the genus, previous studies (Tan et al., 1998) have
found that not all bioactive species appear to contain artemisinin. For
example, Rustaiyan et al. (2009) and Rustaiyan and Masoudi (2011)
reported in A. diﬀusa a new sesquiterpene lactone (tehranolide), which
they consider could be responsible of the antimalarial activity of this
species, given the relevance of the peroxide bridge in this medicinal
property (Shandilya et al., 2013), though such activity yet awaits to be
tested. However, variation of composition and quantity of specialised
metabolites within species is well known and can depend on collection
site, seasonality, or induction by for example herbivory (Wink, 2003;
Moore et al., 2014; Maldonado et al., 2017). It is therefore likely that
further investigation of multiple specimens per species may conﬁrm the
ability to produce artemisinin also in these species. It is also possible,
that artemisinin analogues or other compound types (e.g. coumarins,
polymethoxyﬂavones or ﬂavonoids) could be responsible for the ac-
tivity or possibly act in synergy with artemisinin. More detailed analysis
of compounds and their potential antimalarial activity would be re-
quired to explore this further.
Having comprehensive understanding of the evolutionary relation-
ships among species can help to systematically identify candidate taxa
for further exploration. In Artemisia, this is even more important since
traditional and molecular classiﬁcations sometimes reveal intricate and
conﬂicting evolutionary relationships.
Species lacking morphological aﬃnities can be closely related based
on DNA sequence data, and more interestingly, such relationships have
been further supported when the biochemical pathways have been
taken into account (Greger, 1988). As an example, while there is lack of
morphological aﬃnity between A. keiskena and A. palustris (subg. Ar-
temisia) with representatives of subg. Dracunculus, their close
phylogenetic placement (Fig. S3) is also supported by the fact that they
share speciﬁc dehydrofalcarinone derivatives and aromatic acetylenes,
which are absent in other lineages (Greger, 1988). Therefore, future
drug discovery eﬀorts should focus on exploring the full metabolome
across the phylogenetic diversity of the genus to account for other po-
tentially useful compounds. A main conclusion of the present study is
that artemisinin is much more widespread in the genus than previously
documented.
4.2. Traditional knowledge and ethics
Naturally, extreme caution regarding conservation of genetic re-
sources and intellectual property of indigenous peoples needs to be
taken while carrying out bioprospecting eﬀorts stemming from tradi-
tional knowledge. The Convention on Biological Diversity (CBD) (www.
cbd.int) has been an important milestone to assigning ownership of
traditional knowledge and genetic resources to local communities.
However, our study reveals a gap in the existing framework of in-
tellectual rights. The phylogenetic approach to bioprospecting pre-
sented here combines traditional knowledge and phylogeny to identify
lineages with high bioactivity potential. As we demonstrate, these
lineages may include species for which no use reports exist in tradi-
tional knowledge. Although we argue that this feature is one of the
main strengths of our approach, it also unearths a grey area in the
existing framework. If novel biological resources are identiﬁed, to
whom may intellectual rights be assigned? This is a complex ethical
issue when knowledge from several cultures is advised, like in the
present study. Although creating interdisciplinary bioprospecting ef-
forts can safeguard the ethical aspects of bioprospecting (Saslis-
Lagoudakis and Clarke, 2013), we call for the CBD and policy makers to
formally discuss this issue, in order to be able to fully acknowledge the
power of traditional knowledge from local communities.
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